ASSUMPTIONS AND DEFINITIONS
To limit inconsistencies in interpretation, specific assumptions were considered by the writing group in developing the decision pathway.
General Clinical Assumptions
1. This algorithm is only for patients with NVAF. 6. This algorithm assumes that the clinician will seek additional input from the prescribing physician, cardiologist, and proceduralist to guide clinical judgment, in tandem with patient preference.
Definitions
Definitions of terms used throughout the indication set are listed here.
Bridging:
The process whereby an OAC is discontinued and replaced by a subcutaneous or intravenous anticoagulant before and/or following an invasive procedure.
Temporary interruption:
The process whereby an anticoagulant is stopped for $1 doses, resulting in full or partial dissipation of anticoagulant effect prior to the invasive procedure.
Nonvalvular AF: AF in the absence of rheumatic mitral stenosis, a mechanical or bioprosthetic heart valve, or mitral valve repair.
Periprocedural: The period of time prior to, during, and shortly after an invasive procedure. In a recent retrospective review evaluating 140,420 patients with AF in the Swedish nationwide health registries (6), the annual ischemic stroke rate in those with a CHA 2 DS 2 -VASc score of 1 was lower (0.1% to 0.2% for women and 0.5% to 0.7% for men) than previously estimated. In addition, a retrospective cohort of Taiwanese patients demonstrated that an age of 65 to 74 years was a more powerful predictor of stroke in both men and women compared with other CHA 2 DS 2 -VASc score factors (24) . As such, it comes as no surprise how difficult it can be to settle on a single risk-benefit ratio for anticoagulation in all populations.
Ultimately, before one can determine whether TI is required for a given procedure, it is important to first understand: 1) the propensity for bleeding with the procedure; 2) the clinical effect of bleeding should it occur; and 3) whether patient factors that impart increased bleed risk are present. 
Assessing Procedural Bleed Risk

Assessing Patient-Related Bleed Risk
Beyond the bleed risks inherent to a given procedure, it is important to also assess patient-related factors that may impart increased bleed risk ( Table 1) . These include a history of prior bleeding events (particularly in the Even though the HAS-BLED score has been shown to have predictive value in the periprocedural setting (54), it is limited by its modest discriminatory performance (52) and is not specifically endorsed by current guidelines for this purpose. Instead, cut points for rates of major bleeding have been suggested to differentiate procedures associated with high versus low bleed risk. In 1 review, procedures were considered to be high risk if the major bleed rate within 48 hours was 2% to 4% and low risk if the rate was 0% to 2% (38). In another, high versus low risk levels were defined by procedural rates of major bleeding >1.5% versus #1.5%, respectively (39). This latter cut point was based on criteria previously set by the American Society for Gastrointestinal Endoscopy for individuals on no antithrombotic therapy (55) , and as such, may not accurately reflect the bleed risk for patients on more complex antithrombotic regimens (36).
For patients taking a VKA:
Warfarin is the most commonly prescribed VKA world- Guidance Statement for determining whether a VKA should be interrupted periprocedurally:
1. Do not interrupt therapy with a VKA in:
n Patients undergoing procedures with: 1) no clinically important or low bleed risk; AND 2) absence 4. In those on a higher VKA maintenance dose (7.5 to 10 mg/day or higher) or for whom the INR is known to normalize more quickly, a shorter discontinuation time may be required prior to the procedure. It is important to bear in mind the pharmacokinetics of DOACs. Due to variation between the peak and trough drug levels during the dosing interval with regular once or twice daily dosing, a procedure performed at the trough level (end of a dosing interval) of a DOAC may allow it to be restarted the evening of or the day after the procedure with only 1 or in some cases no dose(s) of the drug missed. For example, in those taking a oncedaily DOAC (e.g., 6:00 PM), some procedures could be performed during the afternoon with the prior evening dose given and a plan to restart the DOAC either: 1) later that day (i.e., 10:00 PM) without a missed dose; or 2) the following day (e.g., 6:00 PM) with only 1 missed dose.
Alternatively, in those taking a twice-daily DOAC (e.g., 9:00 AM and 9:00 PM), some procedures could be performed during the late morning with the prior evening dose given and a plan to restart the DOAC either: 1) that evening (e.g., 6:00 PM) with a single missed dose;
or 2) the following morning (e.g., 9:00 AM) with 2 missed doses.
Since the DOACs became clinically available, 1 persistent concern regarding their use has been the lack of a specific reversal agent in the case of major bleeding complications. This is particularly germane in the peri- Guidance Statement for interruption of a DOAC periprocedurally:
1. Interrupt therapy for low bleed-risk procedures in:
n Patients treated with any of the approved DOACs for a duration based on the estimated CrCl (Table 2 ).
Interrupt therapy for intermediate, high, or uncertain bleed-risk procedures in:
n Patients treated with any of the approved DOACs for a duration based on the estimated CrCl (Table 2) .
Periprocedural DOAC Use With Neuraxial Procedures
Use of anticoagulants in the setting of neuraxial anesthesia raises the risk of a spinal or epidural hematoma, which could be catastrophic. All currently available Doherty et al. setting, the CHA 2 DS 2 -VASc score can be used to assess an individual patient's thrombotic risk overall. As the thrombotic risk increases, the need for bridging becomes more apparent, unless a compelling risk of bleeding is present (36).
Interruption and Bridging for Patients on DOACs
Given the short-half lives of DOACs, bridging with a parenteral agent is rarely, if ever, needed prior to procedures. Reinitiation of these agents after the procedure, however, may need to be delayed owing to the risk of postprocedural bleeding. Reinitiation might also be delayed depending upon: 1) the need for additional procedures; and/or 2) the patient's ability to tolerate oral medications. In these latter 2 circumstances, a shortacting parenteral anticoagulant (e.g., unfractionated
heparin [UFH]) may be needed either between procedures or post-procedure, when thrombotic risk remains high.
Depending on the indication (e.g., venous thromboembolism prophylaxis), a prophylactic dose of UFH or LMWH may be sufficient. These are very specific scenarios that are uncommon in routine clinical practice.
Interruption and Bridging for Patients on a VKA
Patients at Low Thrombotic Risk
Long-term thrombotic risk in NVAF rises proportionally with the CHA 2 DS 2 -VASc score, especially among patients with prior stroke, TIA, or systemic embolism (14, 68, 69) . For patients with a CHA 2 DS 2 -VASc score #4 and no prior history of ischemic stroke or TIA, the risk for a thrombotic event is low (<5%/year) (8) . As such, these patients may discontinue the VKA prior to the procedure as articulated, with resumption when it is felt to be safe from a procedural bleed risk standpoint, as discussed in the following text. Therefore, under most circumstances, no preprocedural or postprocedural parenteral anticoagulation is recommended.
Guidance Statement for determining appropriateness for bridging in those on a VKA who are at low risk for thromboembolism:
1. For patients who are at low risk for thromboembolism (<5%/year), with a CHA 2 DS 2 -VASc score #4 or and no prior history of ischemic stroke, TIA, or SE, discontinue the VKA prior to the procedure and resume as discussed in the following text, without bridging.
Patients at Moderate Thrombotic Risk
For individuals who are at moderate risk for thrombotic events with a CHA 2 DS 2 -VASc score of 5 to 6 or prior history of embolic ischemic stroke, TIA, or systemic embolism ($3 months previously), it is important to assess the patient's bleed risk to determine the optimal approach to Determine the patient's bleed risk to determine the appropriateness of bridging therapy.
If increased risk of bleeding, interruption of the VKA
without bridging is recommended.
If no significant bleed risk:
a. In patients with prior stroke, TIA, or SE, consider 
Patients at High Thrombotic Risk
Patients who are at high thrombotic risk for stroke or SE, such as those with a CHA 2 DS 2 -VASc $7 or with a recent Guidance Statement for determining appropriateness for bridging in those on a VKA at high risk for thromboembolism:
1. For patients who are at high risk of stroke or systemic embolism (>10% per year) with a CHA 2 DS 2 -VASc score of 7 to 9 or recent (within 3 months) ischemic stroke, TIA, or SE, parenteral bridging anticoagulation should be considered.
Specific Recommendations Regarding Bridging
Use of bridging with a parenteral anticoagulant is common, yet the bulk of current evidence suggests that it is associated with an increased risk of both major adverse cardiovascular events and major bleeding, without a significant decrease in thromboembolic events (17, 18, 42, 70 CrCl is <30 mL/min, UFH is preferred over an LMWH; however, dosing guidance for an LMWH is available for patients with a CrCl of 15 to 30 mL/min, although caution is advised when using an LMWH in this setting.
Therapeutic anticoagulation is recommended until the time of procedure. UFH may be discontinued 4 to 6 hours prior to the procedure, with guidance using the activated partial thromboplastin time for earlier time points. If an LMWH is used for bridging, it will need to be discontinued at least 24 hours prior to the procedure (and potentially earlier in those with renal insufficiency), with the option, JACC VOL. 69, NO. 7, 2017 Doherty et al. Table 2) .
Guidance Statement for preprocedural management of parenteral bridging anticoagulation for those on a VKA:
1. Although UFH or a LMWH is most commonly used for bridging, for those with an active or remote history of heparin-induced thrombocytopenia, nonheparin 3. Discontinue UFH ‡4 hours prior to the procedure; the residual anticoagulant effect may be measured by the activated partial thromboplastin time.
4. Discontinue LMWH at least 24 hours prior to the procedure; the residual anticoagulant effect may be measured by an LMWH-specific antifactor Xa assay.
Postprocedural Reinitiation of Anticoagulant Therapy
Restarting anticoagulation in the postprocedural setting may place the patient at significant risk for bleeding. In 3. Consider patient-specific factors that may predispose the patient to bleeding complications (e.g., bleeding diathesis, platelet dysfunction, antiplatelet medications).
Restarting VKA Therapy
Once hemostasis is achieved and no obvious bleeding Guidance Statement for the postprocedural timing of VKA reinitiation:
1. In most situations, a VKA can be restarted in the first 24 hours after the procedure at the patient's usual therapeutic dose.
Indications for Postprocedural Parenteral Bridging and
Unique Postprocedural Indications 
Restarting Anticoagulation After a Procedure With an Unknown Bleed Risk
The timing of restarting anticoagulation discussed in the previous text is largely based on the bleed risk of the procedure performed. However, for procedures with an unknown bleed risk, it is difficult to provide precise guidance regarding the timing of restarting anticoagulation. As previously noted, published rates of periprocedural thromboembolism are low, yet the bleed risk following these procedures is unknown. Therefore, in the absence of evidence-based data, we recommend approaching reinitiation of anticoagulation as was previously recommended for high bleed-risk procedures. This will delay the reinitiation of anticoagulation after the procedure; however, it will not significantly increase the thromboembolic risk for most patients.
Restarting DOAC Therapy Following Cardiac Surgery
The indication for a DOAC should be re-evaluated after 
DISCUSSION AND IMPLICATION OF PATHWAY
The primary objective of this document was to provide a framework for the multiple decisions that need to be made when managing a patient on anticoagulation who is undergoing a procedure. Management of anticoagulation crosses many different specialties. We have attempted to cite the literature to offer direct guidance when possible JACC VOL. 69, NO. 7, 2017 Doherty et al.
and to highlight areas in which clinical judgment is needed.
As more information becomes available, especially regarding the DOACs, many of these areas will be clarified.
This is a clinical area of high volume, with multiple transitions of care and several providers involved in the patient's care, which creates potential risk. It is hoped that this document will aid in the management of our patients. 
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